Compare Sanofi SA (SNY) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.99. The key difference: Sanofi SA pays a 5.5% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none. Which is the better fit depends on your goals.
| SNY | USOI | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $61.17 |
52-Week Low | $41.33 | $42.27 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USOI, the Credit Suisse X-Links Crude Oil Shares Covered Call ETN, trades at $46.84, up 0.09% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The instrument's exceptionally high yield, cited as over 30% by 24/7 Wall Street on 2026-05-19, draws investor attention amid oil market volatility driven by geopolitical events like the Iran War, as reported on 2026-04-26. Key support sits at $45 with resistance at $47.
The outlook hinges on crude oil price movements and covered call strategy performance, offering high income potential but carrying significant risks from oil volatility and the ETN structure, which differs from traditional ETFs. Investors face concentration risk in energy markets and potential capital erosion if oil trends lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
